Pfiz­er took a Phase III shot at re­pur­pos­ing its old drug silde­nafil as a new com­bi­na­tion ther­a­py for per­sis­tent pul­monary hy­per­ten­sion in in­fants. And failed.

Ap­proved in pill form for erec­tile dys­func­tion (Vi­a­gra) and PAH (Re­va­tio), re­searchers took an IV for­mu­la­tion added to in­haled ni­tric ox­ide in­to a piv­otal tri­al in PPHN for new­borns. The study proved that it was no bet­ter at re­duc­ing treat­ment fail­ure or time on ni­tric ox­ide than ni­tric ox­ide alone.

Pul­monary hy­per­ten­sion in­volves the con­stric­tion of pul­monary ar­ter­ies, which forces the heart to work hard­er to pump blood to the lungs. It’s called per­sis­tent pul­monary hy­per­ten­sion in new­borns, a rare and some­times fa­tal con­di­tion that de­creas­es the flow of oxy­gen as the nor­mal change­up in blood flow at birth fails to oc­cur.

Re­va­tio was ap­proved for PAH 14 years ago and has been wide­ly dis­trib­uted around the globe. That came 7 years af­ter the same ac­tive in­gre­di­ent was ap­proved as Vi­a­gra, now 21 years old in mar­ket­ing years. A com­pa­ny called Novi­tium ob­tained a gener­ic ap­proval for PAH just days ago.

So­cial im­age: Kristof­fer Trip­plaar, AP Im­ages

Celyad’s view on developing and delivering a CAR T-cell therapy with multi-tumor specificity combined with cell manufacturing success
Overview
Transitioning potential therapeutic assets from academia into the commercial environment is an exercise that is largely underappreciated by stakeholders, except for drug developers themselves. The promise of preclinical or early clinical results drives enthusiasm, but the pragmatic delivery of a therapy outside of small, local testing is most often a major challenge for drug developers especially, including among other things, the manufacturing challenges that surround the production of just-in-time and personalized autologous cell therapy products.

The ads piqued interest as soon as they started appearing in 2016: at Grand Central Station, on the Red Line in Cambridge, and on a billboard off the New Jersey Turnpike. All showed a young person, generally with his or her arms crossed, and the question, “what is Vivitrol?”

Vivitrol’s maker, Alkermes, was in the midst of a marketing and lobbying campaign to promote the anti-opioid addiction drug — a campaign that would face significant backlash for tarnishing competitors despite little evidence for Vivitrol’s superiority.

The FDA in-house review highlights a disagreement of investigators’ use of a key endpoint by Horizon Pharma in the late-stage trial for the top drug in its pipeline, but largely agreed that the antibody was effective.

Horizon submitted a BLA for thyroid eye disease (TED) drug teprotumumab in March, less than two years after they bought the drug (and the rest of a division) from Narrow River for $145 million upfront. With breakthrough status, priority review, orphan designation and in-house sales projections of up to $750 million, the one-time Roche reject became the marquee pipeline asset for a company that’s developed some of the world’s most expensive drugs.

Seattle Genetics $SGEN is showing off more positive data around tucatinib, its pivotal-stage drug for HER2 positive breast cancer.

A month after hearing about solidly upbeat hazard ratios, we learned today that the estimated progression-free survival rate at one year was 33% in the tucatinib arm compared to 12% for patients taking trastuzumab and capecitabine alone.

Median PFS was 7.8 months (95% CI: 7.5, 9.6) in the tucatinib arm, compared to 5.6 months (95% CI: 4.2, 7.1) in the control arm.

It’s a case of some bad timing for Intec.

Just when a key trial testing the company’s Accordion drug delivery tech imploded in Parkinson’s disease, they handed Novartis data from a successful PK study of a custom Accordion pill engineered to deliver a Novartis compound to entice the Swiss drugmaker into signing a licensing agreement.

Novartis said thanks, but no thanks.

For the cash-strapped Israeli drug developer, the failure to clinch the deal marks a big blow. As of the third quarter, the company has $15.7 million in cash and equivalents, which HC Wainwright analysts estimate will keep the lights on into mid-2020.

When the FDA spurned Astellas’ pitch for atrial fibrillation drug vernakalant in 2008, regulators made it abundantly clear that it wasn’t the efficacy they had a problem with — two Phase III trials had shown the drug successfully restored 52% of patients’ heartbeat from irregular to normal — but the cardio safety issues for a drug that was to compete with well established, low-risk options. One licensing deal, one clinical hold and several studies later, the chances of approval aren’t looking any better.